Phase I/II study to evaluate the safety and clinical efficacy of atezolizumab (atezo; aPDL1) in combination with temozolomide (TMZ) and radiation in patients with newly diagnosed glioblastoma (GBM).

被引：1
|
作者：
Weathers, Shiao-Pei S.
Kamiya-Matsuoka, Carlos
Harrison, Rebecca A.
Liu, Diane D.
Dervin, Shannon
Yun, Cindy
Loghin, Monica Elena
Penas-Prado, Marta
Majd, Nazanin
Yung, W. K. Alfred
O'Brien, Barbara Jane
De Groot, John Frederick
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Genentech Inc, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2511
引用
收藏
页数：2
相关论文
共 50 条
  • [1] SAFETY RUN-IN RESULTS OF A PHASE I/II STUDY TO EVALUATE THE SAFETY AND CLINICAL EFFICACY OF ATEZOLIZUMAB (ATEZO; aPDL1) IN COMBINATION WITH TEMOZOLOMIDE (TMZ) AND RADIATION IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
    Weathers, Shiao-Pei
    Kamiya-Matsuoka, Carlos
    Dervin, Shannon
    Yun, Cindy
    Loghin, Monica
    O'Brien, Barbara
    Harrison, Rebecca
    Yung, W. K. Alfred
    Penas-Prado, Marta
    de Groot, John
    NEURO-ONCOLOGY, 2018, 20 : 9 - 10
  • [2] PHASE I/II STUDY TO EVALUATE THE SAFETY AND CLINICAL EFFICACY OF ATEZOLIZUMAB (ATEZO) IN COMBINATION WITH TEMOZOLOMIDE (TMZ) AND RADIATION IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
    Weathers, Shiao-Pei
    Kamiya-Matsuoka, Carlos
    Harrison, Rebecca
    Liu, Diane
    Sanqui, Edmund
    Dervin, Shannon
    Yun, Cindy
    Loghin, Monica
    Penas-Prado, Marta
    Majd, Nazanin
    Yung, W. K. Alfred
    O'Brien, Barbara
    de Groot, John
    NEURO-ONCOLOGY, 2020, 22 : 35 - 35
  • [3] BIOMARKER IMMUNE CORRELATES IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM) TREATED WITH ATEZOLIZUMAB IN COMBINATION WITH TEMOZOLOMIDE (TMZ) AND RADIATION
    Weathers, Shiao-Pei
    Knafl, Mark
    Parra, Edwin
    Hernandez, Sharia
    Solis, Luisa
    Espiridion, Beatriz Sanchez
    Wistuba, Ignacio
    Futreal, Andrew
    Maru, Dipen
    Kamiya-Matsuoka, Carlos
    Harrison, Rebecca
    Joseph, Victory
    Yun, Cindy
    Darbonne, Walter
    Loghin, Monica
    Penas-Prado, Marta
    Majd, Nazanin
    Yung, W. K. Alfred
    O'Brien, Barbara
    Scott, Woodman
    DeGroot, John
    NEURO-ONCOLOGY, 2021, 23 : 49 - 49
  • [4] Phase II trial of talampanel in conjunction with standard radiation (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM)
    Grossman, S. A.
    Ye, X.
    Chamberlain, M. C.
    Mikkelsen, T.
    Batchelor, T. T.
    Desideri, S.
    Piantadosi, S.
    Fine, H. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] Baseline tumor genomic and gut microbiota association with clinical outcomes in newly diagnosed glioblastoma (GBM) treated with atezolizumab in combination with temozolomide (TMZ) and radiation.
    Weathers, Shiao-Pei S.
    Zhu, Haifeng
    Knafl, Mark
    Damania, Ashish
    Kamiya-Matsuoka, Carlos
    Harrison, Rebecca A.
    Lyons, Larry
    Yun, Cindy
    Darbonne, Walter C.
    Loghin, Monica
    Penas-Prado, Marta
    Majd, Nazanin
    Yung, W. K. Alfred
    O'Brien, Barbara Jane
    Wistuba, Ignacio Ivan
    Futreal, Andrew
    Wargo, Jennifer Ann
    Ajami, Nadim J.
    Woodman, Scott Eric
    De Groot, John Frederick
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] A PHASE I TRIAL OF AFATINIB AND RADIOTHERAPY (RT) WITH OR WITHOUT TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
    Saran, Frank
    James, Allan
    McBain, Catherine
    Jefferies, Sarah
    Harris, Fiona
    Cseh, Agnieszka
    Pemberton, Karine
    Schaible, Jennifer
    Bender, Shaun
    Brada, Michael
    NEURO-ONCOLOGY, 2018, 20 : 20 - 20
  • [7] SAFETY AND EFFICACY EVALUATION OF A PHASE II STUDY OF BORTEZOMIB IN COMBINATION WITH TEMOZOLOMIDE AND REGIONAL RADIATION THERAPY FOR UPFRONT TREATMENT OF PATIENTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM)
    Kong, Xiao-Tang
    Nguyen, Nhung
    Choi, Yoon
    Zhang, Guicheng
    Nguyen, Huytram
    Filka, Emese
    Green, Stacy
    Yong, William
    Liau, Linda
    Kaprealian, Tania
    Pope, Whitney
    Nghiemphu, Phioanh
    Cloughesy, Timothy
    Lassman, Andrew
    Lai, Albert
    NEURO-ONCOLOGY, 2017, 19 : 12 - 12
  • [8] NCCTG phase I trial of temsirolimus (CCI-779) and temozolomide (TMZ) in combination with radiation therapy (RT) in newly diagnosed glioblastoma multiforme (GBM) patients
    Sarkaria, J. N.
    Galanis, E.
    Wu, W.
    Giannini, C.
    Jaeckle, K. A.
    Doyle, L.
    Uhm, J.
    Brown, P.
    Dietz, A. B.
    Buckner, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [9] NUTMEG: A RANDOMISED PHASE II STUDY OF NIVOLUMAB AND TEMOZOLOMIDE (TMZ) VS TMZ ALONE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM): TRIAL IN PROGRESS
    Khasraw, Mustafa
    McDonald, Kerrie
    Yip, Sonia
    Verhaak, Roel
    Heimberger, Amy
    Hall, Merryn
    Fisher, Lauren
    Barnes, Elizabeth
    Rosenthal, Mark
    Gedye, Craig
    Hovey, Elizabeth
    Ellingson, Benjamin
    Simes, John
    Tognela, Annette
    Koh, Eng-Siew
    Gan, Hui
    Back, Michael
    Lwin, Zarnie
    NEURO-ONCOLOGY, 2018, 20 : 235 - 235
  • [10] NUTMEG: A randomised phase II study of nivolumab and temozolomide (TMZ) versus TMZ alone in elderly patients with newly diagnosed glioblastoma (GBM): Trial in progress
    Khasraw, Mustafa
    McDonald, Kerrie L.
    Yip, Sonia
    Verhaak, Roel
    Heimberger, Amy
    Hall, Merryn
    Fisher, Lauren
    Barnes, Elizabeth
    Rosenthal, Mark
    Gedye, Craig
    Hovey, Elizabeth
    Ellingson, Benjamin M.
    Simes, John
    Tongela, Annette
    Wheeler, Helen
    Koh, Eng-Siew
    Gan, Hui
    Back, Michael
    Lwin, Zarnie
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 196 - 197
12345